1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Sanofi (SAN) - Product Pipeline Analysis, 2015 Update

Sanofi (SAN) - Product Pipeline Analysis, 2015 Update

  • March 2015
  • -
  • Global Data
  • -
  • 52 pages

Summary

Sanofi is a diversified global healthcare company. It undertakes the discovery, development and marketing of therapeutic solutions. The company offers a broad range of prescription medicines, and consumer healthcare and generic products worldwide..The company offers Pharmaceutical products in the areas of cancer, cardiovascular diseases, thrombosis, diabetes, central nervous system (CNS) disorders, general diseases such as benign prostatic hyperplasia, osteoporosis and rheumatoid arthritis. Sanofi offers vaccines such as pediatric combinations and poliomyelitis vaccines, influenza, adult and adolescent booster, meningitis, travel and endemic, and measles, mumps and rubella (MMR). It also provides an array of medicines and vaccines for a wide range of animal species. Sanofi is headquartered in Paris, France.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Sanofi
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Table Of Contents

Sanofi (SAN) - Product Pipeline Analysis, 2015 Update
Table of Contents


Table of Contents 2

List of Tables
4

List of Figures
4
Sanofi Company Snapshot 5
Sanofi Company Overview 5
Key Information 6
Sanofi Pipeline Products and Clinical Trials Overview 6
Sanofi - Pipeline Analysis Overview 9
Business Description 9
Key Facts 10
Sanofi - Major Products and Services 11
Sanofi Pipeline Products by Development Stage 13
Sanofi Clinical Trials by Trial Status 15
Sanofi Pipeline Products Overview 17
Fix-Flex Device 17
Fix-Flex Device Product Overview 17
MACI 18
MACI Product Overview 18
MACI Clinical Trial 19
ST01 Bone Graft Substitute Material 20
ST01 Bone Graft Substitute Material Product Overview 20
ST03 Activated Implant 21
ST03 Activated Implant Product Overview 21
ST04 Activated Injectable 22
ST04 Activated Injectable Product Overview 22
ST05 23
ST05 Product Overview 23
Sanofi - Key Competitors 24
Sanofi - Key Employees 25
Sanofi - Key Employee Biographies 27
Sanofi - Locations And Subsidiaries 28
Head Office 28
Other Locations and Subsidiaries 28
Recent Developments 45
Sanofi, Recent Developments 45
Mar 06, 2015: Sanofi Appoints Robert Castaigne As Audit Committee Chairman 45
Feb 27, 2015: Genzyme Recognizes International Rare Disease Day with Global Education and Fund-Raising Events; Announces Founding Partnership of Give RARE 45
Feb 19, 2015: Sanofi Appoints Olivier Brandicourt As Chief Executive Officer 47
Feb 11, 2015: Sanofi To Layoff 100 Employees In Massachusetts 47
Feb 05, 2015: Sanofi delivers Business EPS growth of 7.3% at CER in 2014 47
Dec 22, 2014: Lieff Cabraser Announces Class Action Litigation Against Sanofi 49
Dec 10, 2014: Sanofi Interim CEO Says Company To Continue Diversification 49
Nov 20, 2014: Sanofi Outlines Next Wave of Innovative Medicines and Vaccines 50
Nov 18, 2014: Sanofi Names Chief Scientific Officer Gary Nabel As Sanofi Ebola Response Coordinator 51
Nov 18, 2014: Sanofi Nominates Professor Bonnie L. Bassler To Its Board Of Directors 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52


List of Tables

Sanofi, Key Facts 6
Sanofi Pipeline Products and Clinical Trials Overview 6
Sanofi Pipeline Products by Equipment Type 7
Sanofi Pipeline Products by Indication 8
Sanofi Clinical Trials by Trial Status 8
Sanofi, Key Facts 10
Sanofi, Major Products and Services 11
Sanofi Number of Pipeline Products by Development Stage 13
Sanofi Pipeline Products Summary by Development Stage 14
Sanofi Clinical Trials by Trial Status 15
Sanofi Clinical Trials Summary 16
Fix-Flex Device - Product Status 17
Fix-Flex Device - Product Description 17
MACI - Product Status 18
MACI - Product Description 18
MACI - An Extension Protocol for Subjects Who Completed Genzyme-Sponsored Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of Matrix-Induced Autologous Chondrocyte Implantation (MACI Implant) for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle Including the Trochlea 19
ST01 Bone Graft Substitute Material - Product Status 20
ST01 Bone Graft Substitute Material - Product Description 20
ST03 Activated Implant - Product Status 21
ST03 Activated Implant - Product Description 21
ST04 Activated Injectable - Product Status 22
ST04 Activated Injectable - Product Description 22
ST05 - Product Status 23
ST05 - Product Description 23
Sanofi, Key Employees 25
Sanofi, Key Employee Biographies 27
Sanofi, Other Locations 28
Sanofi, Subsidiaries 29


List of Figures

Sanofi Pipeline Products by Equipment Type 7
Sanofi Pipeline Products by Development Stage 13
Sanofi Clinical Trials by Trial Status 15

Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Diabetes & Obesity Drug Development Pipeline Review, 2016

Diabetes & Obesity Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Diabetes & Obesity Drug Development Pipeline Review, 2016 Summary The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type ...

Ophthalmology Drug Development Pipeline Review, 2016

Ophthalmology Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Ophthalmology Drug Development Pipeline Review, 2016 Summary Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, ...

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.